Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment

Journal of Dermatological Treatment

Volumn 31, Issue 3, 2020, Pages 264-269

  Cabral, Renata Tavares de Souza ^a   Klumb, Evandro Mendes ^a,b   Carneiro, Sueli ^b,c  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

adherence to treatment; Antimalarial maculopathy; lupus erythematosus; questionnaires; rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DIZZINESS; DRY EYE; DRY SKIN; EYE PAIN; EYE REDNESS; FEAR; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; OCULAR PRURITUS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STRUCTURED QUESTIONNAIRE; TINNITUS; TREATMENT DURATION; HEADACHE; PATHOLOGY; PSYCHOLOGY; QUESTIONNAIRE; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT;

ADULT; ANTIMALARIALS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; CROSS-SECTIONAL STUDIES; FEMALE; HEADACHE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85063773004     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546634.2019.1595504     Document Type: Article

References (33)

1. OMS, Organización Mundial de la Salud, Consejo Ejecutivo, 117na Reunión. Prevención de la ceguera y discapacidad visual evitables [Informe de la Secretaría], EB117/35; 22 de diciembre de 2005.
2. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–784.
3. Bernatsky S, Pineau C, Joseph L, et al. Adherence to ophthalmologic monitoring for antimalarial toxicity in a lupus cohort. J Rheumatol. 2003;30:1756–1760.
4. Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol. 2011;38:2504–2508.
5. Arana AL, Arana J, Hasimoto AR, et al. Tomografia de coerência óptica na avaliação da camada de fibras nervosas peripapilar nos usuários de cloroquina. Arq Bras Oftalmol. 2010;73:28–32.
6. Marmor MF, Kellner U, Lai TYY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Am Acad Ophthalmol. 2010;118:415–422.
7. Frances C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148:479–484.
8. Durcan L, Clarke WA, Magder LS, et al. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–2097.
9. Kanski JJ. Clinical ophthalmology: a systematic approach. In: Doenças sistêmicas. Vol. 6. Rio de Janeiro: Elsevier; 2008. p. 869–921.
10. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria. Arthritis Rheumat. 2010;62:2569–2581.
11. Michaelides M, Stover NB, Francis PJ, et al. Retinal toxicity associated with hydroxychloroquine and chloroquine. Arch Ophthalmol. 2011;129:30–39.
12. Kanski JJ. Clinical ophthalmology: a systematic approach. In: Distúrbios Induzidos por medicamentos. Vol. 6. Rio de Janeiro: Elsevier; 2008. p. 841–844.
13. Pasadhika S, Fishman GA, Choi D, et al. Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. Contin Med Educ J. 2010;24:756–763.
14. Mibner S, Kellner U. Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol. 2012;250:319–325.
15. Chen E, Brown DM, Benz MS, et al. De domínio espectral optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sing). Clin Ophthalmol. 2010;4:1151–1158.
16. Rodriguez-Padilla JA, Hedges IIT, Monson BBS, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125:775–780.
17. Stepien KR, Han DP, Schell J, et al. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc. 2009;107:28–34.
18. [acessado dia 20 de Março de 2015 as 20:00h]. Available from: http://www.heidelbergengineering.com/
19. Turgut B, Turkcuoglu P, Serdar Koca S, et al. Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. Clin Rheumatol. 2009;28:607–609.
20. Neto LB, Mesquita AS. Toxic maculopathy caused by antimalarial drugs - detection using de domínio espectral OCT: case reports. Arq Bras Oftalmol. 2009;72:710–714.
21. Prudente LR, Diniz JdeS, Ferreira TX, et al. Medication adherence in patients in treatment for rheumatoid arthritis and systemic lupus erythematosus in a university hospital in Brazil. Patient Prefer Adherence. 2016;19:863–870.
22. Gouveia EB, Morales MSA, Gouveia GB, et al. Toxicidade ocular por derivados da 4-aminoquinolona. Arq Bras Oftalmol. 2007;70:1046–1051.
23. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133:649–656.
24. Marmor MF, Kellner U, Lai TY, et al. American academy of ophthalmology statement recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–1394.
25. Oliveira-Santos M, Verani JdS, Camacho LAB, et al. Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial. Trials. 2016;17:181.
26. Laurindo IMM, Ximenes AC, Lima FAC, et al. Artrite Reumatóide: diagnóstico e tratamento. Projeto Diretrizes da Sociedade Brasileira de Reumatologia; 2002. [Acessado dia 19-05-2012 as 11:00h e disponível no site]. Available from: http://www.projetodiretrizes.org.br/projeto_diretrizes/015.pdf
27. Farhangian ME, Huang WW, Feldman SR. Adherence to oral and topical medications in cutaneous lupus erythematosus is not well characterized. Dermatol Ther (Heidelb). 2015;5:91–105.
28. Laçava AC. Complicações oculares da terapêutica com a cloroquina e derivados. Arq Bras Oftalmol. 2010;73:384–389.
29. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75:25–34.
30. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–1460.
31. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–28.
32. Werner L, Trindade F, Pereira F, et al. Fisiologia da acomodação e presbiopia. Arq Bras Oftalmol. 2000;63:487–493.
33. Ponchet M, Vilela MAC, Sinahara KKS, et al. Avaliação dos efeitos adversos desencadeados pelo uso de difosfato de cloroquina, com ênfase na retinotoxicidade, em 350 doentes com lupus eritematoso. An Bras Dermatol. 2005;80:S275–S282.